Generex Biotechnology (Generex Biotechnology) EPS Growth Rate (Future 3Y To 5Y Estimate) : N/A (As of Jun. 03, 2024)

View and export this data going back to 1998. Start your Free Trial

What is Generex Biotechnology EPS Growth Rate (Future 3Y To 5Y Estimate)?

EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, Generex Biotechnology's EPS Growth Rate (Future 3Y To 5Y Estimate) is N/A.

Competitive Comparison of Generex Biotechnology's EPS Growth Rate (Future 3Y To 5Y Estimate)

For the Biotechnology subindustry, Generex Biotechnology's EPS Growth Rate (Future 3Y To 5Y Estimate), along with its competitors' market caps and EPS Growth Rate (Future 3Y To 5Y Estimate) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Generex Biotechnology's EPS Growth Rate (Future 3Y To 5Y Estimate) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Generex Biotechnology's EPS Growth Rate (Future 3Y To 5Y Estimate) distribution charts can be found below:

* The bar in red indicates where Generex Biotechnology's EPS Growth Rate (Future 3Y To 5Y Estimate) falls into.

Generex Biotechnology (OTCPK:GNBTQ) EPS Growth Rate (Future 3Y To 5Y Estimate) Explanation

EPS Growth Rate (Future 3Y To 5Y Estimate) s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

Generex Biotechnology EPS Growth Rate (Future 3Y To 5Y Estimate) Related Terms

Thank you for viewing the detailed overview of Generex Biotechnology's EPS Growth Rate (Future 3Y To 5Y Estimate) provided by GuruFocus.com. Please click on the following links to see related term pages.

Generex Biotechnology (Generex Biotechnology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Generex Biotechnology Corp (OTCPK:GNBTQ) » Definitions » EPS Growth Rate (Future 3Y To 5Y Estimate)

Comparable Companies

RBSH MRPI BOM:531207 HSTC PPCB NUGX BOM:506365 CDXI IMUN RSPI

Traded in Other Exchanges

N/A

Address

10102 USA Today Way, Miramar, FL, USA, 33025

Website

https://www.generex.com

Generex Biotechnology Corp is a Biotechnology company which is primarily engaged in the research and development of drug delivery systems and technologies. It mainly focuses on developing technology for the administration of formulations of large molecule drugs to the oral (buccal) cavity using a hand-held aerosol applicator. The company operates in the single segment being the Research and development of drug delivery systems and technologies for metabolic and immunological diseases. In addition, the company engages in developing proprietary vaccine formulations through its subsidiaries that work by stimulating the immune system to either attack offending agents that is cancer cells, bacteria, and viruses or to stop attacking benign elements.

Executives

Prioletti Mark Joseph Se	director	1121 PALMER COURT CRYSTAL LAKE IL 60014
Salvo Lawrence Anthony Sr	director	450 ALTON ROAD APT 3704 MIAMI BEACH FL 33139
Harold Gray Haines	other: Consultant	11511 SW 127TH ST MIAMI FL 33176
Mark Fletcher	officer: EVP General Counsel &Secretary	4145 NORTH SERVICE ROAD, SUITE 200 BURLINGTON A6 L7L6A3
Brian Mcgee	director	201 BRIDGELAND AVE TORONTO ONTARIO CANDA M6A 1Y7 A6 00000
Anderson James H Jr.	director	33 HARBOUR SQUARE TORONTO A6 M5J2G2
Mark Corrao	officer: CFO & Treasurer	531 AIRPORT NORTH OFFICE PARK, FORT WAYNE IN 46825
Purcell Richard David Jr.	director, officer: SVP of Research & Drug Develop	65 FAIR HAVEN ROAD, FAIR HAVEN NJ 07704
Gary Herbert Lyman	director	10102 USA TODAY WAY MIRAMAR FL 33025
Kevin Centofanti	director	10102 USA TODAY WAY MIRAMAR FL 33025
Andrew Ro	director, officer: SVP & Chief Investment Officer	10102 USA TODAY WAY MIRAMAR FL 33025
David Brusegard	officer: Chief Operating Officer	4145 NORTH SERVICE ROAD, SUITE 200 BURLINGTON A6 L7L6A3
Stephen Fellows	officer: Chief Financial Officer	33 HARBOUR SQUARE SUITE 202 TORONTO A6 M5J 2G2
Hofe Eric Von	director, officer: President of Subsidiary	4145 NORTH SERVICE ROAD, SUITE 200 BURLINGTON A6 L7L6A3
John P Barratt	director	555 RICHMOND ST. W, SUITE 604 TORONTO A6 M5V3B1